These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: results of a multicenter trial. The Flecainide Supraventricular Tachycardia Study Group. Hopson JR; Buxton AE; Rinkenberger RL; Nademanee K; Heilman JM; Kienzle MG Am J Cardiol; 1996 Jan; 77(3):72A-82A. PubMed ID: 8607395 [TBL] [Abstract][Full Text] [Related]
4. Guidelines for the use of propafenone in treating supraventricular arrhythmias. Kishore AG; Camm AJ Drugs; 1995 Aug; 50(2):250-62. PubMed ID: 8521758 [TBL] [Abstract][Full Text] [Related]
5. [Antiarrhythmic therapy in patients with heart failure]. Faber TS; Zehender M Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993 [TBL] [Abstract][Full Text] [Related]
7. European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias. Coumel P; Leclercq JF; Assayag P Am J Cardiol; 1984 Nov; 54(9):60D-66D. PubMed ID: 6208770 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic considerations in the treatment of common cardiac arrhythmias. Hart NJ Cardiovasc Clin; 1981; 12(2):107-15. PubMed ID: 6178507 [TBL] [Abstract][Full Text] [Related]
9. Clinical applications of antiarrhythmic drugs. Lavenne F; de Jonghe D Acta Cardiol Suppl; 1980; (25):27-42. PubMed ID: 6155012 [No Abstract] [Full Text] [Related]
10. Sotalol. An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias. Fitton A; Sorkin EM Drugs; 1993 Oct; 46(4):678-719. PubMed ID: 7506652 [TBL] [Abstract][Full Text] [Related]
11. [Cardiac arrhythmias in the elderly]. Guize L; Piot O; Lavergne T; Le Heuzey JY Bull Acad Natl Med; 2006; 190(4-5):827-41; discussion 873-6. PubMed ID: 17195610 [TBL] [Abstract][Full Text] [Related]
12. Calcium ion antagonists in supraventricular and ventricular arrhythmias. Schamroth L Cardiology; 1982; 69 Suppl():140-3. PubMed ID: 7151075 [No Abstract] [Full Text] [Related]
13. Dofetilide: a new class III antiarrhythmic agent. Roukoz H; Saliba W Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):9-19. PubMed ID: 17187453 [TBL] [Abstract][Full Text] [Related]
14. Advanced electrophysiologic mapping systems: an evidence-based analysis. Medical Advisory Secretariat Ont Health Technol Assess Ser; 2006; 6(8):1-101. PubMed ID: 23074499 [TBL] [Abstract][Full Text] [Related]
15. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group. Vos MA; Golitsyn SR; Stangl K; Ruda MY; Van Wijk LV; Harry JD; Perry KT; Touboul P; Steinbeck G; Wellens HJ Heart; 1998 Jun; 79(6):568-75. PubMed ID: 10078083 [TBL] [Abstract][Full Text] [Related]
16. Dofetilide: a new drug to control cardiac arrhythmia. Elming H; Brendorp B; Pedersen OD; Køber L; Torp-Petersen C Expert Opin Pharmacother; 2003 Jun; 4(6):973-85. PubMed ID: 12783593 [TBL] [Abstract][Full Text] [Related]
17. Amiodarone -- waxed and waned and waxed again. Doggrell SA Expert Opin Pharmacother; 2001 Nov; 2(11):1877-90. PubMed ID: 11825323 [TBL] [Abstract][Full Text] [Related]
18. Arrhythmias and antiarrhythmic agents. Heddle WF; Tonkin AM Med J Aust; 1984 Nov; 141(11):715-8. PubMed ID: 6503764 [No Abstract] [Full Text] [Related]
19. A benefit-risk assessment of class III antiarrhythmic agents. Brendorp B; Pedersen O; Torp-Pedersen C; Sahebzadah N; Køber L Drug Saf; 2002; 25(12):847-65. PubMed ID: 12241126 [TBL] [Abstract][Full Text] [Related]
20. [Rational bases for the therapy of supraventricular tachycardias and their management]. Rostagno C; Bertini G; Padeletti L; Michelucci A; Del Pace S; Gensini GF Ann Ital Med Int; 1993; 8(4):235-43. PubMed ID: 8161480 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]